IRCT2013041311356N2
Completed
未知
Comparison of Effects Metformin and pioGlutazon on Serum Osteoprotegerin and adiponectin in Patients with Type 2 diabetes in clinic of Imam Khomeini 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diabetes.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •determination of Type 2 diabetes with ADA criteria (FBS\=126 or HbA1C\=6\.5\) and patients with newly diagnosed diabetes. Exclusion criteria: history of hurt failure; Creatine \> 1\.5 mg/dl; liver failure; history of malignancy and being treated with insulin or other glucose\-lowering drugs.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.diabetes mellitus II.non-insulin-dependent diabetes mellitusIRCT201109067482N1Qazvin University of Medical Sciences40
Completed
Not Applicable
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetesJPRN-UMIN000001891Jikei University School of Medicine20
Recruiting
Phase 1
Comparison of the effect Of Metformin and Pioglitazone on hypertriglyceridemia(Dyslipidemia)Condition 1: Hypertriglyceridemia. Condition 2: Metabolic syndrom.Pure hyperglyceridemiaMetabolic syndromeE78.1E88.81IRCT20230618058524N1Islamic Azad University68
Completed
Not Applicable
Effect of metformin, pioglitazone and vitaminE E in patients with non-alcoholic fatty liver diseasenon-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedIRCT2016010411991N3Vice chancellor for research,Kermanshah University of Medical Sciences93
Completed
Phase 4
To study the differences in the effects of various drugs in patients suffering from metabolic syndrome, which is a cluster of conditions such as obesity, increased blood pressure and disordered cholesterol levels that increases the risk of heart diseases, diabetes and stroke.Health Condition 1: null- Metabolic SyndromeCTRI/2014/10/005139Department of Pharmacology140